<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596399</url>
  </required_header>
  <id_info>
    <org_study_id>GV29259</org_study_id>
    <nct_id>NCT02596399</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers</brief_title>
  <official_title>A PHASE I, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY,TOLERABILITY, AND PHARMACOKINETICS OF DSTA4637S IN HEALTHY VOLUNTEERS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study&#xD;
      in healthy volunteers, enrolled at a single site in the United States to investigate the&#xD;
      safety, tolerability, and pharmacokinetics of DSTA4637S.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2015</start_date>
  <completion_date type="Actual">May 30, 2016</completion_date>
  <primary_completion_date type="Actual">May 30, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with at least 1 Adverse Event (AE)</measure>
    <time_frame>Up to Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of analytes of DSTA4637S in plasma and serum</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of anti-therapeutic antibodies (ATA) to DSTA4637S</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>DSTA4637S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSTA4637S</intervention_name>
    <description>Participants will receive DSTA4637S intravenously on Day 1.</description>
    <arm_group_label>DSTA4637S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo matched to DSTA4637S intravenously on Day 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  Able to comply with the study protocol, in the investigator's judgment&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 32 kilogram per square meters (kg/m^2), inclusive&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             12-lead electrocardiogram (ECG), and vital signs&#xD;
&#xD;
          -  Clinical laboratory evaluations should be within the reference range for the test&#xD;
             laboratory unless deemed not clinically significant by the investigator and Sponsor&#xD;
&#xD;
          -  Willing to abstain from the use of drugs of abuse through completion of the study&#xD;
&#xD;
          -  Willing to abstain from use of over the counter, herbal or prescription&#xD;
             medications/products from 14 days prior to Day 1 through completion of the study,&#xD;
             unless deemed acceptable by the investigator and Sponsor&#xD;
&#xD;
          -  Agreeable to, and deemed able to (by the investigator), comply with requirements of&#xD;
             the study, including the follow-up period&#xD;
&#xD;
          -  Willing to abstain from consumption of alcohol-based products from 72 hours prior to&#xD;
             Day 1 until Phase 1 unit check-out on Day 3 and for 72 hours prior to each follow-up&#xD;
             visit&#xD;
&#xD;
          -  For women of childbearing potential, agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use non-hormonal contraceptive methods that result in a&#xD;
             failure rate of less than (&lt;) 1 percent (%) per year during the treatment period and&#xD;
             for at least 85 days after the last dose of study drug&#xD;
&#xD;
          -  For men, agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures and agreement to refrain from donating sperm, as defined in the&#xD;
             study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any diseases, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that in the&#xD;
             opinion of the investigator or Sponsor contraindicates the use of an investigational&#xD;
             drug or that may affect the interpretation of the results or render the subject at&#xD;
             high risk from treatment complications&#xD;
&#xD;
          -  Use of tobacco, electronic cigarettes, personal vaporizer or electronic nicotine&#xD;
             delivery systems (positive history within 3 months before initiation of dosing on Day&#xD;
             1)&#xD;
&#xD;
          -  Received any vaccine within 14 days prior to screening&#xD;
&#xD;
          -  Pregnant or lactating, or intending to become pregnant within 3 months after screening&#xD;
&#xD;
          -  Positive serum pregnancy test result at screening or Day &amp;#8722;1&#xD;
&#xD;
          -  Received oral antibiotics within 4 weeks before initiation of dosing on Day 1, or&#xD;
             intravenous antibiotics within 8 weeks before initiation of dosing&#xD;
&#xD;
          -  Hospitalization within 4 weeks before initiation of dosing&#xD;
&#xD;
          -  Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or&#xD;
             human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
          -  History of significant drug abuse within 1 year prior to screening or use of soft&#xD;
             drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs&#xD;
             (such as cocaine, phencyclidine, and crack) within 1 year prior to screening&#xD;
&#xD;
          -  Positive drug screen at screening or Day -1&#xD;
&#xD;
          -  History of anaphylactic or hypersensitivity drug reaction, unless approved by the&#xD;
             investigator and Sponsor&#xD;
&#xD;
          -  Blood transfusion within 8 weeks prior to screening&#xD;
&#xD;
          -  History of malignancy within 10 years of screening except completely excised basal&#xD;
             cell carcinoma or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  Donation of plasma (greater than or equal to [&gt;=] 500 milliliter [mL]) within 7 days&#xD;
             prior to study drug administration&#xD;
&#xD;
          -  Donation or loss of whole blood (excluding the volume of blood that will be drawn&#xD;
             during screening procedures) as follows: 50-499 mL of whole blood within 30 days or&#xD;
             greater than (&gt;) 499 mL of whole blood within 56 days prior to study drug&#xD;
             administration&#xD;
&#xD;
          -  Hemoglobin &lt;128 gram per liter (g/L) (males) and &lt;115 g/L (females) and hematocrit&#xD;
             &lt;0.37 L/L (males) and &lt;0.32 L/L (females) at screening&#xD;
&#xD;
          -  Poor peripheral venous access&#xD;
&#xD;
          -  History or presence of an abnormal ECG that is clinically significant in the&#xD;
             investigator's opinion, including complete left bundle branch block, second- or&#xD;
             third-degree heart block, evidence of prior myocardial infarction&#xD;
&#xD;
          -  Exposure to any biological therapy or investigational biological agent within 90 days&#xD;
             prior to the screening evaluation or have received any other investigational treatment&#xD;
             30 days prior to the screening evaluation (or within 5 half-lives of the&#xD;
             investigational product, whichever is greater)&#xD;
&#xD;
          -  Any history of hypersensitivity or allergy to rifampin or other rifamycin analogs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International Clinical Pharmacology Center (EDS US Clinic)</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>DSTA4637S</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

